Batimastat

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Batimastat
Batimastat.svg
Clinical data
Pregnancy
category
  • N/A
Routes of
administration
Injection into pleural space or abdomen
ATC code
  • none
Legal status
Legal status
  • Never marketed
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.222.897 Edit this at Wikidata
Chemical and physical data
Formula C23H31N3O4S2
Molar mass 477.64 g/mol
3D model (JSmol)

Batimastat (INN/USAN, codenamed BB-94) is an anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor (MMPI) by mimicking natural MMPI peptides.

Batimastat was the first MMPI that went into clinical trials. First results of a Phase I trial appeared in 1994. The drug reached Phase III but was never marketed; mainly because it couldn't be administered orally (as opposed to the newer and chemically similar MMPI marimastat), and injection into the peritoneum caused peritonitis.[1]

References[edit]

  1. ^ Rothenberg, M. L.; Nelson, A. R.; Hande, K. R. (1999). "New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors". Stem Cells. 17 (4): 237–240. doi:10.1002/stem.170237. PMID 10437989. 

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".